The prevalence of mutations was found to be relatively infrequent (i.e. alteration frequency <10%) across most tumour types except endometrial cancer and melanoma (Fig. 1A), compared to known oncogenic mutations such as KRAS or PIK3CA (Supplementary Fig. 1A, B). Here, PIK3CA is linked to neoplasm.